Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (MBRX)
NASDAQ:MBRX
MBRX Stock Chart & Stats
$6.63
-$0.01(-0.56%)
At close: 4:00 PM EST
$6.63
-$0.01(-0.56%)
Day’s Range― - ―
52-Week Range$6.01 - $91.23
Previous CloseN/A
Volume63.82K
Average Volume (3M)2.74M
Market Cap
$24.59M
Enterprise Value-$2.45M
Total Cash (Recent Filing)$6.70M
Total Debt (Recent Filing)$390.00K
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Mar 20, 2026EPS Estimate
-4.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.88
Shares Outstanding49,498,577
10 Day Avg. Volume1,958,319
30 Day Avg. Volume2,738,732
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)24.47
Price to Sales (P/S)0.00
P/FCF Ratio-6.13
Enterprise Value/Market Cap-0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit30.24
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$4.00Price Target Upside-39.67% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressPhase 3 MIRACLE study recruitment reaches 60% of first 45 patients, underscoring unmet need in r/r AML.
Regulatory PathwayThe adaptive design and early unblinding points provide optionality for the timeline and potential for accelerated regulatory feedback or mid-trial modifications, a favorable design feature.
Treatment PotentialPromising preclinical data demonstrate the potential of Moleculin Biotech's lead asset, annamycin, as a therapeutic agent for liver cancers.
Bears Say
Moleculin Biotech News
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $6.01 and its highest was $91.22 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $24.59M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Mar 20, 2026 which is in 99 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Nov 17, 2025. The company reported -$4.875 earnings per share for the quarter, beating the consensus estimate of -$6.583 by $1.708.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Overvalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -4.38.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 49,498,577 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$4.875 in its last earnings report, beating expectations of -$6.583. Following the earnings report the stock price went down -2.214%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. (MBRX) is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates. The company operates primarily in the biotechnology sector, specializing in the research and development of novel anti-cancer agents. Moleculin's core products include a portfolio of small-molecule drug candidates targeting highly resistant tumors and hard-to-treat cancers. The company's lead compounds are designed to disrupt cancer cell metabolism and enhance the body's immune response against tumors.
MBRX Stock 12 Month Forecast
Average Price Target
$4.00
▼(-39.67% Downside)
Technical Analysis
Ownership Overview
2.19% Insiders
0.24% Mutual Funds
0.09% Other Institutional Investors
97.30% Public Companies and Individual Investors
Options Prices
Currently, No data available
---